AAD Strongly Recommends Arcutis' ZORYVE Cream for Pediatric Atopic Dermatitis
summarizeSummary
Arcutis Biotherapeutics' ZORYVE (roflumilast) cream has received a strong recommendation, backed by high certainty of clinical evidence, in the American Academy of Dermatology's (AAD) first-ever pediatric atopic dermatitis guidelines. The guidelines specifically recommend ZORYVE cream for children aged 2-5 years and 6 years and older with mild to moderate atopic dermatitis, citing its efficacy, safety, and tolerability. This is a significant positive development as AAD guidelines are highly influential among dermatologists and are expected to drive increased prescribing and market penetration for ZORYVE in the substantial pediatric atopic dermatitis segment, reinforcing its position as a leading topical therapy.
At the time of this announcement, ARQT was trading at $24.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $12.42 to $31.77. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.